Phyllanthus urinaria Extract Shows Multi-Pathway Protection Against Cisplatin-Induced Kidney Injury in Mice

A preclinical study finds that an aqueous extract of Phyllanthus urinaria L reduces kidney damage, inflammation, apoptosis, and oxidative stress in mice treated with cisplatin, offering a potential nephroprotective strategy but requiring further validation.

Chicago Metrowire Staff
••Healthcare
Phyllanthus urinaria Extract Shows Multi-Pathway Protection Against Cisplatin-Induced Kidney Injury in Mice

An aqueous extract of Phyllanthus urinaria L (PU) significantly attenuated cisplatin-induced acute kidney injury (AKI) in mice, according to a study published in Pediatric Discovery in 2025. The findings, reported by researchers at the Children's Hospital of Chongqing Medical University and affiliated laboratories in Chongqing, China, provide preclinical evidence that PU may protect renal tubular epithelial cells through multiple pathways, suggesting it warrants further study as a potential nephroprotective strategy for patients receiving cisplatin.

The research matters because cisplatin, a widely used chemotherapy drug, causes AKI in nearly 30% of recipients due to its accumulation in renal tubular epithelial cells, where it triggers inflammation, apoptosis, and oxidative stress. Current management relies heavily on renal replacement therapy because effective preventive medicines are lacking. Drug-induced kidney injury accounts for a substantial share of AKI cases, which are common in hospitalized patients and rise sharply in intensive care, yet treatment options remain largely supportive. A nephroprotective adjunct could widen therapeutic options and reduce treatment interruptions for cancer patients.

In the study, 24 male C57BL/6 mice received a single intraperitoneal injection of cisplatin at 20 mg/kg, with the treatment group also receiving PU at 250 mg/kg by oral gavage on days 0–2. Kidney and blood samples were collected on day 4. Cisplatin raised blood urea nitrogen (BUN) and serum creatinine (Scr), disrupted tubular architecture, and increased neutrophil gelatinase-associated lipocalin (NGAL). PU significantly attenuated these changes. It also suppressed pro-inflammatory cytokine genes, lowered apoptosis-related proteins Bax and cleaved caspase-3 while raising Bcl-2, and restored antioxidant defenses by reducing malondialdehyde, increasing superoxide dismutase activity, and restoring NRF2 and NQO1 expression.

The authors said the study provides a multi-pathway rationale for PU in cisplatin-induced AKI, rather than a single-target effect. They emphasized that the mouse data are encouraging but early, and that the next steps should define active compounds, optimize dosing, and test safety and efficacy in clinically relevant models before any patient use is considered. They described the findings as a foundation for translational work, not a clinical recommendation. The study was published with DOI 10.1002/pdi3.70000.

For patients receiving cisplatin, PU is not ready for clinical use on the basis of this mouse study. The findings point to several research priorities: identify the constituents responsible for the effects, confirm target engagement in human cells or organoids, determine whether PU interferes with cisplatin's anticancer activity, and evaluate safety, dosing, and drug interactions. Such work would need to balance kidney protection with unchanged tumor killing. If those questions are addressed, PU could become a candidate for further development as a supportive therapy for cisplatin-associated kidney injury.

Blockchain Registration

QR Code for Blockchain Registration